Cargando…
Endothelial p130cas confers resistance to anti-angiogenesis therapy
Anti-angiogenic therapies, such as anti-VEGF antibodies (AVAs), have shown promise in clinical settings. However, adaptive resistance to such therapies occurs frequently. We use orthotopic ovarian cancer models with AVA-adaptive resistance to investigate the underlying mechanisms. Genomic profiling...
Autores principales: | Wen, Yunfei, Chelariu-Raicu, Anca, Umamaheswaran, Sujanitha, Nick, Alpa M., Stur, Elaine, Hanjra, Pahul, Jiang, Dahai, Jennings, Nicholas B., Chen, Xiuhui, Corvigno, Sara, Glassman, Deanna, Lopez-Berestein, Gabriel, Liu, Jinsong, Hung, Mien-Chie, Sood, Anil K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8860355/ https://www.ncbi.nlm.nih.gov/pubmed/35081345 http://dx.doi.org/10.1016/j.celrep.2022.110301 |
Ejemplares similares
-
Endothelial p130cas confers resistance to anti-angiogenesis therapy
por: Wen, Yunfei, et al.
Publicado: (2022) -
Endothelial p130cas confers resistance to anti-angiogenesis
therapy
por: Wen, Yunfei, et al.
Publicado: (2023) -
Overcoming adaptive resistance to anti-VEGF therapy by targeting CD5L
por: LaFargue, Christopher J., et al.
Publicado: (2023) -
Targeting CCR2(+) macrophages with BET inhibitor overcomes adaptive resistance to anti-VEGF therapy in ovarian cancer
por: Wu, Yutuan, et al.
Publicado: (2022) -
Targeting Forward and Reverse EphB4/EFNB2 Signaling by a Peptide with Dual Functions
por: Xiong, Chiyi, et al.
Publicado: (2020)